September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Sphingosine kinase 2 induces angiogenic effects by enhancing neovascularisation in the mouse model of retinopathy of prematurity
Author Affiliations & Notes
  • Jeanette Christophel
    Dep. of General Pharmacology and Toxicology, Goethe University Hospital, Frankfurt/Main, Germany
  • Lars-Olof Hattenbach
    Department of Ophthalmology, Ludwigshafen Hospital, Ludwigshafen, Germany
  • Josef Pfeilschifter
    Dep. of General Pharmacology and Toxicology, Goethe University Hospital, Frankfurt/Main, Germany
  • Waltraud Pfeilschifter
    Dep. of Neurology, Goethe University Hospital, Frankfurt/Main, Germany
  • Footnotes
    Commercial Relationships   Jeanette Christophel, Goethe University Hospital (E), Novartis Pharma GmbH (F), Novartis Pharma GmbH (R); Lars-Olof Hattenbach, Allergan (C), Allergan (R), Bayer Healthcare (C), Bayer Healthcare (R), Ludwigshafen Hospital (E), Novartis Pharma GmbH (C), Novartis Pharma GmbH (R); Josef Pfeilschifter, Goethe University Frankfurt (E), Novartis Pharma GmbH (F), Roche (C); Waltraud Pfeilschifter, Bayer Healthcare (R), Boehringer Ingelheim (R), Boehringer Ingelheim (F), Goethe University Hospital (E), Novartis Pharma GmbH (F)
  • Footnotes
    Support  Novartis Pharma GmbH
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3187. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jeanette Christophel, Lars-Olof Hattenbach, Josef Pfeilschifter, Waltraud Pfeilschifter; Sphingosine kinase 2 induces angiogenic effects by enhancing neovascularisation in the mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3187.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The roles of Sphingosine kinase 2 (Sphk2), a key regulator of the cell fate dictating Sphingolipid balance, are complex and not well characterized but its dysfunctions has been shown to facilitate the development of various diseases. To decipher the - so far unknown - functions of Sphk2 in retinal vascular diseases, Sphk2 overexpressing mice were used in an experimental model of oxygen-induced retinopathy (OIR).

Methods : Neonatal C57BL/6J (WT) and EllaCrexJos5a (humane Sphk2 expressing mice with C57BL/6J background, leading to a general overexpression of Sphk2) were used in the OIR model. Neonates were subjected to 75% O2 for 5 days (postnatal day (P) 7 to 12) and then returned to room air. Lipid analysis by LC-MS/MS (n=4), immunhistochemistry on wholemount (n=12), and paraffin embedded retina slides (n=3) were performed on P12, P14 and P17 old retinae. Avascular areas and neovascularisation (NV) were analysed with Adobe Photoshop and ImageJ. One-way ANOVA was used for statistical analysis.

Results : Sphk2 overexpression (Sphk2↑) is reducing retinal layer thickness at P12 (outer nuclear layer (ONL): WT 72.33µm±3.26, Sphk2↑ 43.33±1.98, p<0.001), as well as OIR treatment (ONL: WT Normoxie 72.33µm±3.26, WT OIR 53.29±2.85, p<0.001). Furthermore, more deep thick blood vessels are found in Sphk2↑ mice (2.86 fold, p<0.001). In the OIR model, the avascular area at P12 was significantly (p<0.0001) decreased in Sphk2↑ mice (28.34%±4.78; WT 43.30%±3.32). In Sphk2↑ NV is increased from P14 (1.48%, p<0.01) but blood vessels show a more chaotic organization at P17. In this state, Sphk2↑ induces more GFAP-positive Müller cell processes, interestingly glutamine synthetase stainings do not indicate morphologic changes. The proproliferative Sphk2 metabolite Sphingosine-1-phosphate is increased (p<0.001) in Sphk2↑, particular at P17 (43.90pg/mg±5.30) compared to WT (29.18pg/mg±4.24), but is not influenced by OIR treatment.

Conclusions : Our results show that Sphk2 plays a role in the development of the retina and its vascular structure under normal and pathophysiologic conditions, as shown by the reduced vessel loss in the initial stage followed by increased NV with more pathologic vessel formation. Further studies are needed to unravel the cellular and molecular mechanisms to deepen the knowledge regarding Sphk2, especially during pathological angiogenesis.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×